Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M23-422 Long-term Follow-Up Study of RGX-314 in Neovascular Age-related Macular Degeneration
jRCT2073250145Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Gene Therapies
01
Overview
Open-label, single-arm trial of surabgene lomparvovec in exudative macular degeneration, sponsored by AbbVie Inc. Primary endpoints: Incidence of ocular adverse events in the study eye and Incidence of serious adverse events in the study eye. Started May 2026; status: recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2073250145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073250145.